The Claim
Once-weekly subcutaneous retatrutide administration is associated with a reduction in HbA1c by 0.90% and fasting glucose by 1.24 mmol/L in adults with overweight, obesity, and/or type 2 diabetes, indicating improved glycemic control independent of weight loss.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A once-a-week shot called retatrutide may help lower blood sugar levels in people who are overweight, obese, or have type 2 diabetes—even if they don’t lose weight.
See the scientific wording
Once-weekly subcutaneous retatrutide is associated with a reduction in HbA1c by 0.90% and fasting glucose by 1.24 mmol/L in adults with overweight, obesity, and/or type 2 diabetes, indicating improved glycemic control independent of weight loss.
Score breakdown, mechanism chain, raw evidence, ideal studies needed
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.